非小细胞肺癌模型

肺癌（小细胞和非小细胞）是男性和女性中最常见的癌症。大约14％的新癌症是肺癌。美国癌症协会2018年美国肺癌的估计是：

• About 234,030 new cases of lung cancer (121,680 in men and 112,350 in women)
• About 154,050 deaths from lung cancer (83,550 in men and 70,500 in women)

There are two main types of lung cancer, non-small cell (NSCLC) and small cell (SCLC) lung cancer. NSCLC represents ~85% of all lung cancer cases. Lung cancer mainly occurs in older people, with diagnosis occurring at age 65 or older.

Overall, the chance that a man will develop lung cancer in his lifetime is about 1 in 15; for a woman, the risk is about 1 in 17. These numbers include both smokers and non-smokers. For smokers the risk is much higher, while for non-smokers the risk is lower. The lung cancer rate has been dropping among men over the past few decades, but only for about the last decade in women. Many contribute this decline to the significant anti-smoking campaigns and the efforts to keep young adults from ever trying it.

与所有癌症一样，它的预期高度依赖于发现癌症的早期。如果早期发现，预后可能是非常有利的，甚至治疗。然而，由于许多人在很多年内偶然生活，因此早期发现是挑战性的。

Treatment options for NSCLC are surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. In many cases, a combination of multiple treatment types is used. In the last few years there have been several new targeted and immune based therapies approved by the FDA. These drugs are the result of hundreds of hours of preclinical research evaluating novel therapies in cell and animal models.

NSCLC continues to be a histotype of great interest in the research community due to the high rate of new cases diagnosed annually. Targeted therapy has been widely successful but acquired resistance is a recurring issue. To support preclinical research needs, Covance has several well optimized non-small cell lung cancer lines (See Table 1). In this Model Spotlight we highlight a few of our more commonly used lines.(For a complete list of our tumor models点击这里。）

原位HCC827

NCI-H1975

NCI-H1975是由女性非吸烟者建立的。由于其L858R / T790M的突变状态，这种细胞系对研究界感兴趣。在50-60％的NSCLC患者中发现了T790M获得的突变，该患者抵抗1^st和2ⁿ代表皮生长因子受体抑制剂。^1,2因此，该模型适用于评估新颖3^rdgeneration EGFR inhibitors, such as compounds that bind to EGFR regardless of the mutational changes that have occurred, or compounds that bind irreversibly. Also, this model would be valuable when evaluating combination therapies with EGFR inhibitors looking to mitigate resistance to treatment. Subcutaneous tumor growth of the model is reliable and consistent, with tumor volume doubling every 3-4 days and typically reaching evaluation size (~750mm³) in approximately 15 days post implant (See Figures 5 and 6).

皮下NCI-H1975

Pleasecontact usif you are interested in discussing any of our human NSCLC models.

^{1王王，顺东沧，德龙刘建第三代抑制剂靶向EGFR T790M突变在先进的非小细胞肺癌J Hematol Oncol中。2016;9：34。
2Yun M，Kim Eo，Lee D，Kim JH，Kim J，Lee H，Lee J，Kim Sh Melatonin致敏H1975非小细胞肺癌细胞，涉及酪氨酸激酶抑制剂Gefitinib的T790M靶向表皮生长因子受体突变。细胞生物学生物化学。2014; 34（3）：865-72。DOI：10.1159 / 000366305。EPUB 2014 8月21日。
3Girard L, et al. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 60: 4894-4906, 2000. PubMed: 10987304.
Note: Studies were performed in accordance with applicable animal welfare regulations in an AAALAC-accredited facility Note: Studies were performed in accordance with applicable animal welfare regulations in an AAALAC-accredited facility}